Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meletios A Dimopoulos

Showing results (621-630 of 652) with videos related to

Pageof 66
Sort By:
Leukemia|May 4, 2018
Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma NetworkHeinz Ludwig, Michel Delforge, Thierry Facon, et al.
The New England Journal of Medicine|December 9, 2014
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myelomaA Keith Stewart, S Vincent Rajkumar, Meletios A Dimopoulos, et al.
Blood Advances|February 24, 2026
Early Mortality with Bispecific Antibody Therapy in RRMM: An IMWG Immunotherapy Database Real-World AnalysisCarlyn Rose Tan, Saad Z Usmani, Andriy Derkach, et al.
The New England Journal of Medicine|September 4, 2014
Lenalidomide and dexamethasone in transplant-ineligible patients with myelomaLotfi Benboubker, Meletios A Dimopoulos, Angela Dispenzieri, et al.
The Lancet. Haematology|March 1, 2023
Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort studyAnnie Cowan, Federico Ferrari, Samuel S Freeman, et al.
Haematologica|September 22, 2018
Daratumumab plus lenalidomide and dexamethasone <i>versus</i> lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUXMeletios A Dimopoulos, Jesus San-Miguel, Andrew Belch, et al.
Nature Reviews. Clinical Oncology|July 7, 2025
EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myelomaMeletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, et al.
The Lancet. Oncology|December 3, 2014
International Myeloma Working Group updated criteria for the diagnosis of multiple myelomaS Vincent Rajkumar, Meletios A Dimopoulos, Antonio Palumbo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2023
Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN StudyMeletios A Dimopoulos, Stephen Opat, Shirley D'Sa, et al.
American Journal of Hematology|March 23, 2021
Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myelomaHolger W Auner, Maria Gavriatopoulou, Sosana Delimpasi, et al.
Pageof 66

Showing results (621-630 of 652) with videos related to

Sort By:
Pageof 66
Leukemia|May 4, 2018
Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma NetworkHeinz Ludwig, Michel Delforge, Thierry Facon, et al.
The New England Journal of Medicine|December 9, 2014
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myelomaA Keith Stewart, S Vincent Rajkumar, Meletios A Dimopoulos, et al.
Blood Advances|February 24, 2026
Early Mortality with Bispecific Antibody Therapy in RRMM: An IMWG Immunotherapy Database Real-World AnalysisCarlyn Rose Tan, Saad Z Usmani, Andriy Derkach, et al.
The New England Journal of Medicine|September 4, 2014
Lenalidomide and dexamethasone in transplant-ineligible patients with myelomaLotfi Benboubker, Meletios A Dimopoulos, Angela Dispenzieri, et al.
The Lancet. Haematology|March 1, 2023
Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort studyAnnie Cowan, Federico Ferrari, Samuel S Freeman, et al.
Haematologica|September 22, 2018
Daratumumab plus lenalidomide and dexamethasone <i>versus</i> lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUXMeletios A Dimopoulos, Jesus San-Miguel, Andrew Belch, et al.
Nature Reviews. Clinical Oncology|July 7, 2025
EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myelomaMeletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, et al.
The Lancet. Oncology|December 3, 2014
International Myeloma Working Group updated criteria for the diagnosis of multiple myelomaS Vincent Rajkumar, Meletios A Dimopoulos, Antonio Palumbo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2023
Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN StudyMeletios A Dimopoulos, Stephen Opat, Shirley D'Sa, et al.
American Journal of Hematology|March 23, 2021
Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myelomaHolger W Auner, Maria Gavriatopoulou, Sosana Delimpasi, et al.
Pageof 66